17,261 trials
Hypogonadal Males
Primary: Responder Rate: Percentage of Subjects Whose Average Steady State Concentration (Cavg) of Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL Following…
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Embryonal Rhabdomyosarcoma
Primary: Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment — 0.9390 Proportion of Participants
Brain Injuries
Primary: Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group. — 42.750; 50.500; 49.500; 55.000 T-score…
Gout
Primary: Serum Urate Maximum Percentage (%) Change (Emax, CB) — -43.5; -55.6; -70.4; -79.1 Percentage (%) — p=<0.0001
Head and Neck Cancer
Primary: Number of Participants With Complete and Partial Response Using RECIST Criteria — 17; 2 Participants
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants
Advanced or Metastatic Solid Tumors · Advanced or Metastatic Breast Cancer
Primary: Phase I: Percentage of Participants Responding to Treatment — 61.5 percent of participants with response
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Maximum Tolerated Dose and Optimal Tolerated Dose of Pegylated Liposomal Doxorubicin Hydrochloride (Doxil) When Given in Combination With Cyclophosphamide (Phase I) — 30…
Breast Cancer · Skin Reactions Secondary to Radiation Therapy
Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…
Hypophosphatasia (HPP)
Primary: Skeletal Radiograph Evaluation Using a Qualitative Radiographic Global Impression of Change (RGI-C) Scale Compared to Baseline (Pre-treatment) in Study ENB-006-09…
Prostate Cancer
Primary: Proportion of Patients With PSA Response (pt) Within 12 Weeks of Samarium 153 Administration — 7 percentage of participants
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement — 7.7; 28.6; 76.7; 82.8 percentage of participants — p=0.079
Periapical Diseases
Primary: Changes Between Initial and Post Treatment Dimensions of Periapical Lesions — 37.34; 34.04; 16.20; 17.54 square millimeters — p=<0.01
Hemophilia B
Primary: Mean Difference of Area Under the Curve (AUC): BeneFIX Compared to AlphaNine — 10.41 IU x hour/dL — p=0.77